What do systematic reviews say?

Breast surgery plus systemic treatment vs systemic treatment

Breast surgery plus systemic treatment showed no clear difference in toxicity from local therapy compared with systemic treatment (low certainty).

• Breast surgery for metastatic breast cancer 2018 · Cochrane Headline outcomes only
  RR 0.99 [0.14, 6.9]
  1 study · 274 participants
  Low

Intervention not reported

• Home‐based multidimensional survivorship programmes for breast cancer survivors 2017 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 764 participants
  Moderate

Intervention not reported

• Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 97 participants
  Low

Intervention not reported

• Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1956 participants
  Very low

Intervention not reported

• Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 175 participants
  Very low

Intervention not reported

• Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 284 participants
  Very low

Intervention not reported

• Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 284 participants
  Very low

Intervention not reported

• Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 87 participants
  Very low

Intervention not reported

• Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 51 participants
  Low

Intervention not reported

• Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 123 participants
  Low

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in overall survival ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  HR 0.8 [0.6, 1.08]
  2 studies · 947 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines leads to lower adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (high certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.62 [0.4, 0.97]
  4 studies · 279 participants
  High

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in adverse events: neurotoxicity (grade 3/4) ( compared with anthracyclines followed by taxane (low certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.78 [0.25, 2.46]
  3 studies · 162 participants
  Low

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in treatment adherence (defined as dose delay) ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.76 [0.52, 1.12]
  3 studies · 238 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 20 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in disease‐free survival ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  HR 0.84 [0.65, 1.09]
  1 study · 828 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in pathological complete response (no invasive cancer in breast or… compared with anthracyclines followed by taxane (high certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 1.15 [0.96, 1.38]
  4 studies · 1280 participants
  High

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 1.25 [0.86, 1.82]
  1 study · 280 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in adverse events: neurotoxicity (grade 3/4) ( compared with anthracyclines followed by taxane (low certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.95 [0.55, 1.65]
  2 studies · 1108 participants
  Low

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in treatment adherence (defined as dose reduction) ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.81 [0.59, 1.11]
  1 study · 280 participants
  Moderate